TKI Landscape for Ph+ ALL Expanding.

Preliminary phase III findings support using ponatinib, a third-generation tyrosine kinase inhibitor, as part of standard care for adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia. In the PhALLCON trial, ponatinib significantly outperformed imatinib, inducing deeper and more durable responses with no added toxicity.